ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Quantum Surge Drives Wild Options Bets

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Markets wobbled Monday as quantum computing stocks captured options traders' attention. The catalyst: SpaceX shed over $400 billion in market value after its debut rally reversed sharply on rising US bond yields.

That rotation sent options flow into quantum names fast. IonQ carries 15.2% short interest of free float. Its options chain runs from this Friday all the way out to September 18. Traders with active June 26 expiries are sitting on tight timeframes — any further quantum-driven volatility could force rapid unwinding.

Rigetti Computing tells a similar story. Short interest sits at 19.4% of free float. Availability of shares to borrow stands at just 68% of SI, signalling moderate squeeze risk. Options expiries cluster in weekly increments through August.

Meanwhile, IBM — now in the spotlight after Trump's quantum policy moves — carries a modest 3.4% short interest. Its near-term June 26 and July expiries point to near-dated positioning. Options traders appear to be placing event-driven bets on IBM's quantum narrative.

Marvell Technology stands out with the most densely packed expiry calendar among today's movers. Contracts expire as frequently as two to three times weekly through September. That density suggests elevated hedging activity around AI chip exposure.

With SpaceX spillover still rippling, options flow in quantum and AI names bears close watching into quarter-end.

Stocks in this article

How this article was generated

Generated
23 Jun 2026, 12:57
Prompt version
v1.0
Data sources
Options flowORTEX Alpha signals

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.